A Comparative Analysis of SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Evotec SE

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Madrigal Pharmaceuticals, Inc. and Evotec SE from 2014 to 2023. Over this period, Evotec SE consistently outpaced Madrigal Pharmaceuticals in SG&A spending, with a notable increase of approximately 843% from 2014 to 2023. In contrast, Madrigal Pharmaceuticals saw a significant rise of around 587% in the same timeframe.

Key Insights

• Evotec SE: By 2023, Evotec's SG&A expenses reached nearly 170 million, reflecting its aggressive expansion and operational strategies.
• Madrigal Pharmaceuticals, Inc.: Despite a lower starting point, Madrigal's expenses surged to over 108 million by 2023, indicating robust growth and investment in administrative capabilities.

This financial trajectory highlights the strategic priorities and market positioning of these two pharmaceutical giants.